These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 27497829

  • 1. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
    Ohashi K, Hotta K, Hirata T, Aoe K, Kozuki T, Ninomiya K, Kayatani H, Yanai H, Toyooka S, Hinotsu S, Takata M, Kiura K.
    Clin Lung Cancer; 2017 Jan; 18(1):92-95. PubMed ID: 27497829
    [Abstract] [Full Text] [Related]

  • 2. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA.
    Cancer J; 2015 Jan; 21(5):357-64. PubMed ID: 26389758
    [Abstract] [Full Text] [Related]

  • 3. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT, Pérez-Fidalgo JA, Martín-Martorell P, Cejalvo JM, Pons V, Bermejo B, Martín M, Albanell J, Lluch A.
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [Abstract] [Full Text] [Related]

  • 4. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.
    J Clin Oncol; 2017 Sep 10; 35(26):3046-3054. PubMed ID: 28682681
    [Abstract] [Full Text] [Related]

  • 5. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
    Morimura O, Minami T, Kijima T, Koyama S, Otsuka T, Kinehara Y, Osa A, Higashiguchi M, Miyake K, Nagatomo I, Hirata H, Iwahori K, Takimoto T, Takeda Y, Kida H, Kumanogoh A.
    Biochem Biophys Res Commun; 2017 Jul 08; 488(4):596-602. PubMed ID: 28526406
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.
    J Clin Oncol; 2012 Sep 10; 30(26):3234-41. PubMed ID: 22649126
    [Abstract] [Full Text] [Related]

  • 7. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
    Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR.
    Mol Cancer; 2014 Jun 05; 13():143. PubMed ID: 24898067
    [Abstract] [Full Text] [Related]

  • 8. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.
    Curr Med Res Opin; 2013 Apr 05; 29(4):405-14. PubMed ID: 23402224
    [Abstract] [Full Text] [Related]

  • 9. A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
    Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K.
    J Thorac Oncol; 2018 Feb 05; 13(2):273-279. PubMed ID: 29313813
    [Abstract] [Full Text] [Related]

  • 10. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I, Winer EP.
    Clin Cancer Res; 2014 Jan 01; 20(1):15-20. PubMed ID: 24135146
    [Abstract] [Full Text] [Related]

  • 11. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
    Haddley K.
    Drugs Today (Barc); 2013 Nov 01; 49(11):701-15. PubMed ID: 24308017
    [Abstract] [Full Text] [Related]

  • 12. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM, Boster BL, Barnett CM.
    J Oncol Pharm Pract; 2015 Apr 01; 21(2):132-42. PubMed ID: 24682654
    [Abstract] [Full Text] [Related]

  • 13. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB, Wildiers H, Krop IE, Smitt M, Yu R, Lysbet de Haas S, Gonzalez-Martin A.
    Int J Cancer; 2016 Nov 15; 139(10):2336-42. PubMed ID: 27428671
    [Abstract] [Full Text] [Related]

  • 14. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
    Perez EA, Hurvitz SA, Amler LC, Mundt KE, Ng V, Guardino E, Gianni L.
    Breast Cancer Res; 2014 May 23; 16(3):R50. PubMed ID: 24887458
    [Abstract] [Full Text] [Related]

  • 15. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA.
    J Clin Oncol; 2013 Mar 20; 31(9):1157-63. PubMed ID: 23382472
    [Abstract] [Full Text] [Related]

  • 16. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD.
    Clin Exp Metastasis; 2015 Jan 20; 32(1):29-38. PubMed ID: 25398397
    [Abstract] [Full Text] [Related]

  • 17. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
    Cancer Med; 2014 Oct 20; 3(5):1256-65. PubMed ID: 24890382
    [Abstract] [Full Text] [Related]

  • 18. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, Chernyukhin N, Smitt MC, Krop IE.
    J Clin Oncol; 2014 Sep 01; 32(25):2750-7. PubMed ID: 25024070
    [Abstract] [Full Text] [Related]

  • 19. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.
    Noguchi E, Tamura K, Hattori M, Horiguchi J, Sato N, Kanatani K, Matsunaga K, Iwata H, Fujiwara Y.
    Breast Cancer; 2019 Jan 01; 26(1):39-46. PubMed ID: 30039339
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.
    J Clin Oncol; 2011 Feb 01; 29(4):398-405. PubMed ID: 21172893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.